nach oben

Endocrine

Erschienen in:

14.07.2020 | Original Article

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy

verfasst von: Lin Run, Liping Wang, Xiting Nong, Nan Li, Xin Huang, Yang Xiao

Erschienen in: Endocrine | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Thyroid carcinoma is the most frequent endocrine malignancy with high occurrence of BRAFV600E mutations. Though targeted therapy by vemurafenib, a specific inhibitor for BRAFV600E, has achieved great advance in therapeutic landscape, resistance occurrence is still a clinical challenge. Here, we sought to elucidate the function of high mobility group box 1 (HMGB1) in vemurafenib resistance in thyroid cancer harboring BRAF mutation.

Methods

The expression of HMGB1 in BRAF-mutant BCPAP and BRAF-wild CAL-62 cells were determined by qRT-PCR and western. Then, BCPAP cells were transfected with recombinant HMGB1 plasmids, and vemurafenib-resistant BCPAP-R cells were treated with si-HMGB1. The efficacy of HMGB1 on vemurafenib resistance was evaluated by detecting cell viability, apoptosis, and caspase-3 activity. In addition, the involvement of autophagy pathway was investigated.

Results

Lower expression of HMGB1 was observed in BRAF-mutant BCPAP cells that had high sensitivity to vemurafenib. Overexpression of HMGB1 attenuated BCPAP cell sensitivity to vemurafenib by increasing cell viability and decreasing cell apoptosis and caspase-3 activity. Intriguingly, higher expression of HMGB1 was confirmed in vemurafenib-resistant BCPAP-R cells. Moreover, knockdown of HMGB1 sensitized BCPAP-R cells to vemurafenib resistance. Mechanistically, vemurafenib exposure induced autophagy by enhancing LC3II, Beclin-1 expression, and reducing autophagy substrate p62 expression. Importantly, targeting HMGB1 suppressed vemurafenib-induced autophagy. Blocking autophagy pathway with its inhibitor 3-MA offset BCPAP-R cell resistance to vemurafenib.

Conclusions

These findings highlight that HMGB1-mediated autophagy may account for vemurafenib resistance in thyroid cancer harboring BRAF mutation, implying a promising approach to overcome vemurafenib resistance in vemurafenib-mutant thyroid carcinomas.

H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. Jama 317(13), 1338–1348 (2017). https://doi.org/10.1001/jama.2017.2719CrossRefPubMed

H.J. Song, Z.L. Qiu, C.T. Shen, W.J. Wei, Q.Y. Luo, Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eu. J. Endocrinol. 173(3), 399–408 (2015). https://doi.org/10.1530/EJE-15-0296CrossRef

J. Iva, G. Filip, B. Martin, Z. Pavel, C. Jan, The significance of BRAFV600E mutation in thyroid cancer in terms of novel targeted therapies—overview of current knowledge and studies. Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti 31(5), 339–344 (2018). https://doi.org/10.14735/amko2018339

M. Xing, BRAF mutation in thyroid cancer. Endocrine-Rel. Cancer 12(2), 245–262 (2005). https://doi.org/10.1677/erc.1.0978CrossRef

C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, G. Materazzi, R. Elisei, M. Santoro, P. Miccoli, F. Basolo, Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metabol. 92(11), 4085–4090 (2007). https://doi.org/10.1210/jc.2007-1179CrossRef

E. Takacsova, R. Kralik, I. Waczulikova, K. Zavodna, J. Kausitz, A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer. Neoplasma 64(1), 156–164 (2017). https://doi.org/10.4149/neo_2017_120CrossRefPubMed

P.B. Chapman, C. Robert, J. Larkin, J.B. Haanen, A. Ribas, D. Hogg, O. Hamid, P.A. Ascierto, A. Testori, P.C. Lorigan, R. Dummer, J.A. Sosman, K.T. Flaherty, I. Chang, S. Coleman, I. Caro, A. Hauschild, G.A. McArthur, Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals Oncol. 28(10), 2581–2587 (2017). https://doi.org/10.1093/annonc/mdx339CrossRef

W.J. Wei, Z.K. Sun, C.T. Shen, H.J. Song, X.Y. Zhang, Z.L. Qiu, Q.Y. Luo, Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer. Theranostics 7(4), 987–1001 (2017). https://doi.org/10.7150/thno.17322CrossRefPubMedPubMedCentral

C. Garbe, T.K. Eigentler, Vemurafenib. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 211, 77–89 (2018). https://doi.org/10.1007/978-3-319-91442-8_6CrossRefPubMed

10.

L. Yang, Y. Yu, R. Kang, M. Yang, M. Xie, Z. Wang, D. Tang, M. Zhao, L. Liu, H. Zhang, L. Cao, Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leukemia Lymphoma 53(2), 315–322 (2012). https://doi.org/10.3109/10428194.2011.616962CrossRefPubMed

11.

Q. Li, J. Li, T. Wen, W. Zeng, C. Peng, S. Yan, J. Tan, K. Yang, S. Liu, A. Guo, C. Zhang, J. Su, M. Jiang, Z. Liu, H. Zhou, X. Chen, Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. Oncotarget 5(15), 6387–6403 (2014). https://doi.org/10.18632/oncotarget.2201CrossRefPubMedPubMedCentral

12.

M.P. Singh, H.J. Cho, J.T. Kim, K.E. Baek, H.G. Lee, S.C. Kang, Morin hydrate reverses cisplatin resistance by impairing PARP1/HMGB1-dependent autophagy in hepatocellular carcinoma. Cancers 11(7) (2019). https://doi.org/10.3390/cancers11070986

13.

T. Xu, L. Jiang, Z. Wang, The progression of HMGB1-induced autophagy in cancer biology. OncoTargets Therapy 12, 365–377 (2019). https://doi.org/10.2147/OTT.S185876CrossRefPubMed

14.

X. Guan, P. Wang, J. Chi, S. Zhao, F. Wang, Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma. Biochem. Biophys. Res. Commun. 486(4), 898–903 (2017). https://doi.org/10.1016/j.bbrc.2017.03.117CrossRefPubMed

15.

W. Wang, H. Kang, Y. Zhao, I. Min, B. Wyrwas, M. Moore, L. Teng, R. Zarnegar, X. Jiang, T.J. Fahey 3rd, Targeting autophagy sensitizes BRAF-mutant thyroid cancer to Vemurafenib. J. Clin. Endocrinol. Metabol. 102(2), 634–643 (2017). https://doi.org/10.1210/jc.2016-1999CrossRef

16.

E.K. Hanly, R.B. Bednarczyk, N.Y. Tuli, A.L. Moscatello, H.D. Halicka, J. Li, J. Geliebter, Z. Darzynkiewicz, R.K. Tiwari, mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget 6(37), 39702–39713 (2015). https://doi.org/10.18632/oncotarget.4052CrossRefPubMedPubMedCentral

17.

D.M. Hyman, I. Puzanov, V. Subbiah, J.E. Faris, I. Chau, J.Y. Blay, J. Wolf, N.S. Raje, E.L. Diamond, A. Hollebecque, R. Gervais, M.E. Elez-Fernandez, A. Italiano, R.D. Hofheinz, M. Hidalgo, E. Chan, M. Schuler, S.F. Lasserre, M. Makrutzki, F. Sirzen, M.L. Veronese, J. Tabernero, J. Baselga, Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl. J. Med. 373(8), 726–736 (2015). https://doi.org/10.1056/NEJMoa1502309CrossRefPubMedPubMedCentral

18.

T. Wu, W. Zhang, G. Yang, H. Li, Q. Chen, R. Song, L. Zhao, HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget 7(31), 50417–50427 (2016). https://doi.org/10.18632/oncotarget.10413CrossRefPubMedPubMedCentral

19.

S. Mardente, E. Mari, F. Consorti, C. Di Gioia, R. Negri, M. Etna, A. Zicari, A. Antonaci, HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol. Rep. 28(6), 2285–2289 (2012). https://doi.org/10.3892/or.2012.2058CrossRefPubMed

20.

Y.X. Zhang, Y.Q. Yuan, X.Q. Zhang, D.L. Huang, Y.Y. Wei, J.G. Yang, HMGB1-mediated autophagy confers resistance to gemcitabine in hormone-independent prostate cancer cells. Oncol. Lett. 14(5), 6285–6290 (2017). https://doi.org/10.3892/ol.2017.6965CrossRefPubMedPubMedCentral

21.

J. Xia, X. Yu, X. Song, G. Li, X. Mao, Y. Zhang, Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells. Mol. Med. Rep. 15(1), 488–494 (2017). https://doi.org/10.3892/mmr.2016.6003CrossRefPubMed

22.

Y. Shi, W. Gong, L. Lu, Y. Wang, J. Ren, Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells. Braz. J. Med. Biol. Res. 52(11), e8657 (2019). https://doi.org/10.1590/1414-431X20198657CrossRefPubMedPubMedCentral

23.

D. Tang, R. Kang, K.M. Livesey, C.W. Cheh, A. Farkas, P. Loughran, G. Hoppe, M.E. Bianchi, K.J. Tracey, H.J. Zeh 3rd, M.T. Lotze, Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190(5), 881–892 (2010). https://doi.org/10.1083/jcb.200911078CrossRefPubMedPubMedCentral

24.

R. Amaravadi, A.C. Kimmelman, E. White, Recent insights into the function of autophagy in cancer. Genes Dev. 30(17), 1913–1930 (2016). https://doi.org/10.1101/gad.287524.116CrossRefPubMedPubMedCentral

25.

Y.J. Li, Y.H. Lei, N. Yao, C.R. Wang, N. Hu, W.C. Ye, D.M. Zhang, Z.S. Chen, Autophagy and multidrug resistance in cancer. Chin. J. Cancer 36(1), 52 (2017). https://doi.org/10.1186/s40880-017-0219-2CrossRefPubMedPubMedCentral

26.

J.M. Mulcahy Levy, S. Zahedi, A.M. Griesinger, A. Morin, K.D. Davies, D.L. Aisner, B.K. Kleinschmidt-DeMasters, B.E. Fitzwalter, M.L. Goodall, J. Thorburn, V. Amani, A.M. Donson, D.K. Birks, D.M. Mirsky, T.C. Hankinson, M.H. Handler, A.L. Green, R. Vibhakar, N.K. Foreman, A. Thorburn, Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. eLife 6 (2017). https://doi.org/10.7554/eLife.19671

27.

H.K. Byeon, H.J. Na, Y.J. Yang, S. Ko, S.O. Yoon, M. Ku, J. Yang, J.W. Kim, M.J. Ban, J.H. Kim, D.H. Kim, J.M. Kim, E.C. Choi, C.H. Kim, J.H. Yoon, Y.W. Koh, Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. Oncotarget 8(1), 596–609 (2017). https://doi.org/10.18632/oncotarget.13480CrossRefPubMed

28.

H. Li, J. Li, G. Zhang, Q. Da, L. Chen, S. Yu, Q. Zhou, Z. Weng, Z. Xin, L. Shi, L. Ma, A. Huang, S. Qi, Y. Lu, HMGB1-induced p62 overexpression promotes snail-mediated epithelial-mesenchymal transition in glioblastoma cells via the degradation of GSK-3beta. Theranostics 9(7), 1909–1922 (2019). https://doi.org/10.7150/thno.30578CrossRefPubMedPubMedCentral

29.

H.Y. Chang, S.Y. Chen, C.H. Wu, C.C. Lu, G.C. Yen, Glycyrrhizin attenuates the process of epithelial-to-mesenchymal transition by modulating HMGB1 initiated novel signaling pathway in prostate cancer cells. J. Agric. Food Chem. 67(12), 3323–3332 (2019). https://doi.org/10.1021/acs.jafc.9b00251CrossRefPubMed

Titel: Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy
verfasst von: Lin Run
Liping Wang
Xiting Nong
Nan Li
Xin Huang
Yang Xiao
Publikationsdatum: 14.07.2020
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02417-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era

The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

Thyroid function and risk of all-cause and cardiovascular mortality: a prospective population-based cohort study

Antidiabetic compounds 8a, 8b, 8k, and 9h enhance insulin secretion: activity and mechanism

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin